Skip to content
10-Q

Quarterly Report

PharmaCyte Biotech, Inc. PMCB

0001683168-24-006441

← back to feed
Filed
Sep 17, 2024 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2025 · Sep 10, 2024 7.68M sh
Cash And Equivalents Q1 2025 · Jul 31, 2024 $32.64M
Cash And Equivalents Q1 2025 · Apr 30, 2024 $50.18M
Current Liabilities Q1 2025 · Jul 31, 2024 $7.47M
Current Liabilities Q1 2025 · Apr 30, 2024 $7.42M
Total Liabilities Q1 2025 · Jul 31, 2024 $17.15M
Total Liabilities Q1 2025 · Apr 30, 2024 $20.39M
Current Assets Q1 2025 · Jul 31, 2024 $32.88M
Current Assets Q1 2025 · Apr 30, 2024 $50.44M
Total Assets Q1 2025 · Jul 31, 2024 $70.19M
Total Assets Q1 2025 · Apr 30, 2024 $59.9M
Shares Diluted Q1 2025 · Jul 31, 2023 12.6M sh
Stock Repurchased Q1 2025 · Jul 31, 2023 $26.46M
Operating Cash Flow Q1 2025 · Jul 31, 2023 $342.96K
Stockholders Equity restated Q1 2025 · Jul 31, 2023 $39.19M
Stockholders Equity Q1 2025 · Apr 30, 2023 $72.69M
Eps Diluted restated Q1 2025 · Jul 31, 2023 −$0.54
Eps Basic restated Q1 2025 · Jul 31, 2023 −$0.54
Rd Expense Q1 2025 · Jul 31, 2023 $104.48K
Net Income Q1 2025 · Jul 31, 2023 −$3.18M
Operating Income Q1 2025 · Jul 31, 2023 −$2.08M
Revenue Q1 2025 · Jul 31, 2023 $0